About GammaMabs Pharma
GammaMabs Pharma is a biotechnology company developing a new monoclonal antibody targeting gynecological cancers, including ovarian cancer. Ovarian cancer is responsible for over 50 000 deaths every year in Europe and the United States. It has a poor prognosis as it is often diagnosed at an advanced stage due to a lack of systematic screening. Increasing resistance to traditional chemotherapy treatments justifies research into targeted therapeutic solutions, such as monoclonal antibodies.
Missing: GammaMabs Pharma's Product Demo & Case Studies
Promote your product offering to tech buyers.
Reach 1000s of buyers who use CB Insights to identify vendors, demo products, and make purchasing decisions.
Missing: GammaMabs Pharma's Product & Differentiators
Don’t let your products get skipped. Buyers use our vendor rankings to shortlist companies and drive requests for proposals (RFPs).
Expert Collections containing GammaMabs Pharma
Expert Collections are analyst-curated lists that highlight the companies you need to know in the most important technology spaces.
GammaMabs Pharma is included in 1 Expert Collection, including Cancer.
Pharmaceutical and biotechnology companies with cancer therapy drug candidates.
GammaMabs Pharma Frequently Asked Questions (FAQ)
What is GammaMabs Pharma's latest funding round?
GammaMabs Pharma's latest funding round is Series A.
Who are the investors of GammaMabs Pharma?
Investors of GammaMabs Pharma include CDC Entreprises, iXO Private Equity, Bpifrance and LFB Biomedicaments.
Discover the right solution for your team
The CB Insights tech market intelligence platform analyzes millions of data points on vendors, products, partnerships, and patents to help your team find their next technology solution.